In HR+ advanced breast cancer

~40% of your patients share more than just breast cancer^1-3

Learn more about the relevance of PIK3CA Mutations in aBC

Watch the Video now

PIK3CA mutations are found in ~40% of HR+ breast cancer patients and associated with a poor prognosis^1-3,5

Learn more

Alpha isoform selectivity may play a role in the future

Learn more

HR=hormone receptor.

REFERENCES:

Sabine VS, Crozier C, Brookes CL, et al. Mutational analysis of PI3K/AKT signaling pathway in Tamoxifen Exemestane Adjuvant Multinational pathology study. J Clin Oncol. 2014;32(27):2951 - 2958.
Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15(1):7-24.
LoRusso PM. Inhibition of the PI3K/AKT/mTOR pathway in solid tumors. J Clin Oncol. 2016;34(31):3803 - 3815.
Lee JJX, Loh K, Yap Y-S. PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol Med. 2015;12(4):342-354.
Aleskandarany MA, Rakha EA, Ahmed MA, et al. PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. Breast Cancer Res Treat. 2010;122(1):45-53.

~40% of your patients share more than just breast cancer1-3